» Articles » PMID: 22438952

Morpholino-mediated Increase in Soluble Flt-1 Expression Results in Decreased Ocular and Tumor Neovascularization

Overview
Journal PLoS One
Date 2012 Mar 23
PMID 22438952
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Angiogenesis is a key process in several ocular disorders and cancers. Soluble Flt-1 is an alternatively spliced form of the Flt-1 gene that retains the ligand-binding domain, but lacks the membrane-spanning and intracellular kinase domains of the full-length membrane bound Flt-1 (mbFlt-1) protein. Thus, sFlt-1 is an endogenous inhibitor of VEGF-A mediated angiogenesis. Synthetic mopholino oligomers directed against splice site targets can modulate splice variant expression. We hypothesize that morpholino-induced upregulation of sFlt-1 will suppress angiogenesis in clinically relevant models of macular degeneration and breast cancer.

Methods And Findings: In vivo morpholino constructs were designed to target murine exon/intron 13 junction of the Flt-1 transcript denoted VEGFR1_MOe13; standard nonspecific morpholino was used as control. After nucleofection of endothelial and breast adenocarcinoma cell lines, total RNA was extracted and real-time RT-PCR performed for sFlt-1 and mbFlt-1. Intravitreal injections of VEGFR1_MOe13 or control were done in a model of laser-induced choroidal neovascularization and intratumoral injections were performed in MBA-MD-231 xenografts in nude mice. VEGFR1_MOe13 elevated sFlt-1 mRNA expression and suppressed mbFlt-1 mRNA expression in vitro in multiple cellular backgrounds (p<0.001). VEGFR1_MOe13 also elevated sFlt/mbFlt-1 ratio in vivo after laser choroidal injury 5.5 fold (p<0.001) and suppressed laser-induced CNV by 50% (p = 0.0179). This latter effect was reversed by RNAi of sFlt-1, confirming specificity of morpholino activity through up-regulation of sFlt-1. In the xenograft model, VEGFR1_MOe13 regressed tumor volume by 88.9%, increased sFlt-1 mRNA expression, and reduced vascular density by 50% relative to control morpholino treatment (p<0.05).

Conclusions: Morpholino oligomers targeting the VEGFR1 mRNA exon/intron 13 junction promote production of soluble FLT-1 over membrane bound FLT-1, resulting in suppression of lesional volume in laser induced CNV and breast adenocarcinoma. Thus, morpholino manipulation of alternative splicing offers translational potential for therapy of angiogenic disorders.

Citing Articles

Soluble FLT-1 in angiogenesis: pathophysiological roles and therapeutic implications.

Wazan L, Widhibrata A, Liu G Angiogenesis. 2024; 27(4):641-661.

PMID: 39207600 DOI: 10.1007/s10456-024-09942-8.


Vascular endothelial growth factor B inhibits insulin secretion in MIN6 cells and reduces Ca and cyclic adenosine monophosphate levels through PI3K/AKT pathway.

Jia J, Jiang W, Luo X, Li R, Zhao Y, Tian G World J Diabetes. 2021; 12(4):480-498.

PMID: 33889292 PMC: 8040075. DOI: 10.4239/wjd.v12.i4.480.


Alternative splicing in endothelial cells: novel therapeutic opportunities in cancer angiogenesis.

Di Matteo A, Belloni E, Pradella D, Cappelletto A, Volf N, Zacchigna S J Exp Clin Cancer Res. 2020; 39(1):275.

PMID: 33287867 PMC: 7720527. DOI: 10.1186/s13046-020-01753-1.


The sVEGFR1-i13 splice variant regulates a β1 integrin/VEGFR autocrine loop involved in the progression and the response to anti-angiogenic therapies of squamous cell lung carcinoma.

Faycal C, Brambilla E, Agorreta J, Lepeltier N, Jacquet T, Lemaitre N Br J Cancer. 2018; 118(12):1596-1608.

PMID: 29795310 PMC: 6008445. DOI: 10.1038/s41416-018-0128-4.


GSTM3 and GSTP1: novel players driving tumor progression in cervical cancer.

Checa-Rojas A, Delgadillo-Silva L, Del Castillo Velasco-Herrera M, Andrade-Dominguez A, Gil J, Santillan O Oncotarget. 2018; 9(31):21696-21714.

PMID: 29774096 PMC: 5955133. DOI: 10.18632/oncotarget.24796.


References
1.
Elkin M, Orgel A, Kleinman H . An angiogenic switch in breast cancer involves estrogen and soluble vascular endothelial growth factor receptor 1. J Natl Cancer Inst. 2004; 96(11):875-8. DOI: 10.1093/jnci/djh140. View

2.
Miles D, Chan A, Dirix L, Cortes J, Pivot X, Tomczak P . Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2010; 28(20):3239-47. DOI: 10.1200/JCO.2008.21.6457. View

3.
Miller H, Miller B, Ishibashi T, Ryan S . Pathogenesis of laser-induced choroidal subretinal neovascularization. Invest Ophthalmol Vis Sci. 1990; 31(5):899-908. View

4.
Lai C, Shen W, Brankov M, Lai Y, Barnett N, Lee S . Long-term evaluation of AAV-mediated sFlt-1 gene therapy for ocular neovascularization in mice and monkeys. Mol Ther. 2005; 12(4):659-68. DOI: 10.1016/j.ymthe.2005.04.022. View

5.
. Argon laser photocoagulation for neovascular maculopathy. Five-year results from randomized clinical trials. Macular Photocoagulation Study Group. Arch Ophthalmol. 1991; 109(8):1109-14. View